New HIV drug candidate passes first safety check in healthy volunteers
NCT ID NCT05631704
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new experimental HIV drug called VH4524184 in 84 healthy adults to see if it is safe and how the body processes it. The study also looked at whether the drug affects a key liver enzyme. Because HIV requires lifelong treatment, this is not a cure but a step toward better disease control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Baltimore, Maryland, 21225, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop anal lesions from becoming cancer?
- Can resilience defeat HIV stigma? a new study investigates
- Peer support may curb HIV stigma and stress in vietnamese gay men
- A pharmacist's touch: could structured medication reviews boost HIV treatment success?
- A new Fast-Track HIV care model aims to Re-Engage those lost to care
- Can a smartphone app curb HIV risk in south Korea's young gay men?